Capricor Therapeutics presented data from HOPE-3 Open Label Extension study at the 2026 World Muscle Society Congress indicating that deramiocel treatment is associated with a slower decline in upper limb function.
The post Capricor shares new data on arm and hand function with deramiocel appeared first on CureDuchenne.